ABBV-295 vs eloralintide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Amylin receptor · full Obesity pipeline
ABBV-295
Developed by AbbVie under a licence from Gubra
NCT06144684 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Safety - Adverse Events (AE) incidence" (with 2 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: December 2026 · NCT07514260 (registry estimate)
Reported efficacy
Safety - Adverse Events (AE) incidence (from baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C); Safety - changes in vital signs (from baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C); Safety - Safety laboratory parameters (From baseline (day 0) to end of trial (day 29) part 1, (day 64) part 2A, (day 120) part 2B and (day 127) in Part 2C): Two-part first-in-human phase 1 study of subcutaneous ABBV-295, a long-acting amylin analog: ABBV-295 demonstrated a favorable tolerability profile at all evaluated dose levels and no serious adverse events were reported. Treatment showed clinically meaningful body weight reduction from -7.75% to -9.79% (least-squares mean) at week 12 with weekly dosing. (not_applicable)
Result source: NCT06144684
eloralintide
Developed by Eli Lilly
NCT06230523 · Phase 2 · completed
Randomized, double-blind, placebo-controlled phase 2 in obesity and overweight (263 participants). Week-48 body-weight reductions ranged from 9.4% to 20.1% across eloralintide doses versus 0.4% on placebo, a separation many times larger than the reported error margins; percent change in body weight is the accepted registrational endpoint in obesity.
Next expected readout: December 2026 · NCT07738614 (registry estimate)
Reported efficacy
Percent Change From Baseline in Body Weight at Week 48 (Baseline, Week 48): Body weight, percent change from baseline at Week 48: eloralintide 1 mg -9.4%, 3 mg -12.4%, 6 mg -17.6%, 9 mg -20.1%, 6/9 mg -19.9% and 3/6/9 mg -16.5% vs placebo -0.4%. (met)
Result source: NCT06230523
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ABBV-295 | eloralintide |
|---|---|---|
| Body weight, % change | —Not reported | -20.1% vs -0.4%−19.7 vs placeboNCT062305235 other results
|
| Weight loss of 5% or more | —Not reported | 92.7% vs 31.2%+61.5 vs placeboNCT062305235 other results
|
| Weight loss of 10% or more | —Not reported | 82.3% vs 12.8%+69.5 vs placeboNCT062305235 other results
|
| Waist circumference, change (cm) | —Not reported | —Trial running · NCT07321886 |
Body weight, % change
- ABBV-295
- —Not reported
- eloralintide
- -20.1% vs -0.4%−19.7 vs placeboNCT06230523
5 other results
- -19.9% vs -0.4% NCT06230523
- -17.6% vs -0.4% NCT06230523
- -12.4% vs -0.4% NCT06230523
- -9.4% vs -0.4% NCT06230523
- -16.5% vs -0.4% NCT06230523
Weight loss of 5% or more
- ABBV-295
- —Not reported
- eloralintide
- 92.7% vs 31.2%+61.5 vs placeboNCT06230523
5 other results
- 97.5% vs 31.2% NCT06230523
- 85.0% vs 31.2% NCT06230523
- 87.1% vs 31.2% NCT06230523
- 71.5% vs 31.2% NCT06230523
- 90.8% vs 31.2% NCT06230523
Weight loss of 10% or more
- ABBV-295
- —Not reported
- eloralintide
- 82.3% vs 12.8%+69.5 vs placeboNCT06230523
5 other results
- 91.1% vs 12.8% NCT06230523
- 76.6% vs 12.8% NCT06230523
- 60.5% vs 12.8% NCT06230523
- 53.3% vs 12.8% NCT06230523
- 79.2% vs 12.8% NCT06230523
Waist circumference, change (cm)
- ABBV-295
- —Not reported
- eloralintide
- —Trial running · NCT07321886
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ABBV-295: no structured comparison results are available for Obesity.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ABBV-295: 0 of 4 rows · eloralintide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | eloralintide |
|---|---|
| Dropout rate | 20.8%6/9 mga NCT06230523 · Phase 2 show 5 more results11.1%9 mg NCT06230523 · Phase 2 25%6 mg NCT06230523 · Phase 2 20.8%3 mg NCT06230523 · Phase 2 46.4%1 mg NCT06230523 · Phase 2 11.5%3/6/9 mg NCT06230523 · Phase 2 |
| Discontinued due to AEs | 0%6/9 mga NCT06230523 · Phase 2 show 5 more results1.9%9 mg NCT06230523 · Phase 2 3.6%6 mg NCT06230523 · Phase 2 0%3 mg NCT06230523 · Phase 2 7.1%1 mg NCT06230523 · Phase 2 3.8%3/6/9 mg NCT06230523 · Phase 2 |
| Serious AEs | 8.3%6/9 mga NCT06230523 · Phase 2 show 5 more results5.6%9 mg NCT06230523 · Phase 2 3.6%6 mg NCT06230523 · Phase 2 4.2%3 mg NCT06230523 · Phase 2 10.7%1 mg NCT06230523 · Phase 2 1.9%3/6/9 mg NCT06230523 · Phase 2 |
| Most frequent reported AEs | 6/9 mga nausea 54.2% (placebo 13.2%) fatigue 45.8% (placebo 11.3%) upper respiratory tract infection 20.8% (placebo 11.3%) NCT06230523 · Phase 2 show 5 more results9 mg fatigue 42.6% (placebo 11.3%) nausea 33.3% (placebo 13.2%) constipation 24.1% (placebo 5.7%) NCT06230523 · Phase 2 6 mg nausea 64.3% (placebo 13.2%) diarrhoea 35.7% (placebo 9.4%) fatigue 28.6% (placebo 11.3%) NCT06230523 · Phase 2 3 mg constipation 16.7% (placebo 5.7%) arthralgia 12.5% (placebo 5.7%) fatigue 12.5% (placebo 11.3%) NCT06230523 · Phase 2 1 mg benign prostatic hyperplasia 14.3% (placebo 15.4%) constipation 14.3% (placebo 5.7%) covid-19 14.3% (placebo 3.8%) NCT06230523 · Phase 2 3/6/9 mg nausea 25% (placebo 13.2%) fatigue 21.2% (placebo 11.3%) diarrhoea 17.3% (placebo 9.4%) NCT06230523 · Phase 2 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
eloralintide
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABBV-295's landscape · eloralintide's landscape